Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis

医学 氯胺酮 荟萃分析 耐受性 相对风险 重性抑郁障碍 随机对照试验 交叉研究 萧条(经济学) 临床试验 内科学 置信区间 不利影响 麻醉 安慰剂 替代医学 经济 病理 扁桃形结构 宏观经济学
作者
Ying Xu,Maree L. Hackett,Gregory Carter,Colleen Loo,Verònica Gálvez,Nick Glozier,Paul Glue,Kyle Lapidus,Alexander McGirr,Andrew A. Somogyi,Philip B. Mitchell,Anthony Rodgers
出处
期刊:The International Journal of Neuropsychopharmacology [Oxford University Press]
卷期号:19 (4): pyv124-pyv124 被引量:205
标识
DOI:10.1093/ijnp/pyv124
摘要

Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising from crossover trials. A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases up to August 2014. The primary endpoints were change in depression scale scores at days 1, 3 and 7, remission, response, suicidality, safety, and tolerability. Data were independently abstracted by 2 reviewers. Where possible, unpublished data were obtained on treatment effects in the first period of crossover trials. Nine trials were identified, including 201 patients (52% female, mean age 46 years). Six trials assessed low-dose ketamine (0.5mg/kg i.v.) and 3 tested very low-dose ketamine (one trial assessed 50mg intra-nasal spray, another assessed 0.1–0.4mg/kg i.v., and another assessed 0.1–0.5mg/kg i.v., intramuscular, or s.c.). At day 3, the reduction in depression severity score was less marked in the very low-dose trials (P homogeneity <.05) and among bipolar patients. In analyses excluding the second period of crossover trials, response rates at day 7 were increased with ketamine (relative risk 3.4, 95% CI 1.6–7.1, P=.001), as were remission rates (relative risk 2.6, CI 1.2–5.7, P=.02). The absolute benefits were large, with day 7 remission rates of 24% vs 6% (P=.02). Seven trials provided unpublished data on suicidality item scores, which were reduced on days 1 and 3 (both P<.01) but not day 7. Low-dose ketamine appears more effective than very low dose. There is substantial heterogeneity in clinical response, with remission among one-fifth of patients at 1 week but most others having benefits that are less durable. Larger, longer term parallel group trials are needed to determine if efficacy can be extended and to further assess safety.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Bagel完成签到 ,获得积分10
1秒前
深井冰发布了新的文献求助10
1秒前
Wanxian完成签到,获得积分10
1秒前
阳光冰颜完成签到,获得积分10
2秒前
zhhua完成签到,获得积分10
2秒前
阳光的雪碧完成签到,获得积分10
3秒前
Aria完成签到,获得积分10
3秒前
3秒前
科研通AI6应助三更笔舞采纳,获得10
3秒前
昏睡的人完成签到 ,获得积分10
6秒前
量子星尘发布了新的文献求助10
8秒前
光亮笑柳完成签到,获得积分10
9秒前
科研通AI6.1应助zyx采纳,获得30
9秒前
深情安青应助深井冰采纳,获得10
12秒前
12秒前
czl完成签到,获得积分10
14秒前
左丘白桃完成签到,获得积分10
15秒前
leeSongha完成签到 ,获得积分10
15秒前
杨小鸿发布了新的文献求助10
16秒前
16秒前
kingsbro-xu完成签到,获得积分20
19秒前
科研通AI6.1应助三更笔舞采纳,获得10
20秒前
猫猫侠完成签到,获得积分10
20秒前
量子星尘发布了新的文献求助10
23秒前
25秒前
25秒前
25秒前
炙热面包完成签到,获得积分10
27秒前
冰与火发布了新的文献求助20
29秒前
spc68应助xuan采纳,获得10
29秒前
Nara2021发布了新的文献求助20
29秒前
不要慌完成签到 ,获得积分10
29秒前
大个应助杨小鸿采纳,获得10
30秒前
30秒前
31秒前
量子星尘发布了新的文献求助10
31秒前
香香完成签到,获得积分10
33秒前
栀子花开XIXI完成签到,获得积分10
34秒前
34秒前
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Introduction to strong mixing conditions volume 1-3 5000
Ägyptische Geschichte der 21.–30. Dynastie 2500
Human Embryology and Developmental Biology 7th Edition 2000
The Developing Human: Clinically Oriented Embryology 12th Edition 2000
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 2000
„Semitische Wissenschaften“? 1510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5742261
求助须知:如何正确求助?哪些是违规求助? 5407364
关于积分的说明 15344547
捐赠科研通 4883713
什么是DOI,文献DOI怎么找? 2625203
邀请新用户注册赠送积分活动 1574062
关于科研通互助平台的介绍 1531044